RPRX News
  • Repros Therapeutics Q2 Loss Per Share $0.38, Inline With Last Year
    8/11/2014
  • Repros Says Fully Enrolls Second Head To Head Study Of Androxal Versus Topical Testosterone Gel
    5/13/2014
  • Repros Therapeutics Q1 Loss/Shr $0.37 Vs. Loss $0.41 Last Year
    5/12/2014
  • Repros Therapeutics Received FDA Guidance Regarding Primary Endpoints For Two Studies, ZA-304 And ZA-305
    4/30/2014

Next 10 Headlines